-
1 . Academic Journal
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
- 저자
- by Sorli, Christopher; Harashima, Shin-ichi; Tsoukas, George M; Unger, Jeffrey; Karsbøl, Julie Derving, et al.
- 소스
- In The Lancet Diabetes & Endocrinology April 2017 5(4):251-260